Drug Information

Drug (ID: DG01757) and It's Reported Resistant Information

• Name: Navitoclax/Trametinib
• Synonyms: Navitoclax/Trametinib
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colon cancer [ICD-11: 2B90]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [1]

• Molecule Alteration: Missense mutation; p.V600E (c.1799T>A)
• Sensitive Disease: Colon cancer [ICD-11: 2B90.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HT29 Cells; Colon; Homo sapiens (Human); CVCL_A8EZ
• In Vitro Model: A549 cells; Lung; Homo sapiens (Human); CVCL_0023
• In Vitro Model: A2058 cells; Skin; Homo sapiens (Human); CVCL_1059
• In Vitro Model: HPAF-II cells; Pancreatic; Homo sapiens (Human); CVCL_0313
• In Vitro Model: H23 cells; Lung; Homo sapiens (Human); CVCL_1547
• In Vitro Model: WiDR cells; Colon; Homo sapiens (Human); CVCL_2760
• In Vitro Model: SW1573 cells; Lung; Homo sapiens (Human); CVCL_1720
• In Vitro Model: KHM-5M cells; Pleural effusion; Homo sapiens (Human); CVCL_2975
• In Vitro Model: WM793 cells; N.A.; Homo sapiens (Human); CVCL_8787/CVCL_5414
• In Vitro Model: SkMEL-2 cells; Skin; Homo sapiens (Human); CVCL_0069
• In Vitro Model: PANC 0203 cells; Pancreas; Homo sapiens (Human); CVCL_1633
• In Vitro Model: MOR/CPR cells; Lung; Homo sapiens (Human); CVCL_2620
• In Vitro Model: MM415 cells; Lymph node; Homo sapiens (Human); CVCL_2608
• In Vitro Model: HTC-C3 cells; Pleural effusion; Homo sapiens (Human); CVCL_2273
• In Vitro Model: HCC364 cells; Lung; Homo sapiens (Human); CVCL_5134
• In Vitro Model: H2347 cells; Lung; Homo sapiens (Human); CVCL_1550
• In Vitro Model: Calu-1 cells; Lung; Homo sapiens (Human); CVCL_0608
• In Vitro Model: CAL-12T cells; Lung; Homo sapiens (Human); CVCL_1105
• In Vivo Model: NOD-SCID female mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis; qPCR
• Experiment for Drug Resistance: CellTiter-Glo assay; Caspase3/7-Glo iuminescent assay

References

• Ref 1: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesNat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.